全球舞蹈病治疗市场 – 行业趋势及 2030 年预测

舞蹈病治疗市场分析和规模

原发性舞蹈症又称亨廷顿氏病 (HD)，是一种遗传性神经退行性疾病。据估计，全球每 100,000 人中约有 2 至 7 人患有亨廷顿氏病。该病可影响男性和女性，通常在成年期发病，但也有青少年期发病的亨廷顿氏病病例。继发性舞蹈症可由多种因素引起，包括某些药物、代谢紊乱、自身免疫性疾病、感染和脑损伤。继发性舞蹈症的发病率取决于具体的潜在病因，并且可能有很大差异。

Data Bridge Market Research 分析称，全球舞蹈病治疗市场在 2022 年为 6.5157 亿美元，预计到 2030 年将达到 9.6266 亿美元，预计在 2023-2030 年预测期内的复合年增长率为 5.0%。这表明了市场价值。由于对舞蹈病患者更好的治疗方法的需求不断增长，“药物”在全球舞蹈病治疗市场的类型细分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

舞蹈病治疗市场范围和细分

Market Definition

Chorea is referring as a motion disorder which induces unpredictable, irregular, and involuntary muscle movements. Growing awareness regarding chorea symptoms among populace anticipated to enhance the chorea treatment market’s growth rate. The disorder can make individual glance like restless or dancing or fidgety.

Global Chorea Treatment Market Dynamics

Drivers

• Increasing Prevalence of Gastrointestinal Disorders

The rising incidence of gastrointestinal disorders such as colorectal cancer, esophageal cancer, gastric outlet obstruction, and inflammatory bowel disease (IBD) is driving the demand for GI stents. These conditions often require stent placement to relieve symptoms and improve the patient's quality of life.

• Growing Aging Population

The global population is aging, leading to an increased prevalence of age-related conditions like gastrointestinal strictures and cancers. As the elderly population grows, there is a higher demand for GI stents to manage these conditions.

Opportunities

• Expansion of Endoscopic Procedures

Endoscopic procedures, including endoscopic stent placement, are becoming increasingly common for the treatment of gastrointestinal disorders. The expansion of endoscopic techniques, such as endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), provides opportunities for GI stent manufacturers to develop specialized stents for these procedures.

• Focus on Patient-Centric Approaches

Patient comfort, quality of life, and long-term outcomes are crucial considerations in GI stent placement. Companies that prioritize patient-centric approaches, such as designing stents with improved biocompatibility, reduced migration rates, and better ease of removal, can gain a competitive advantage and capture market share.

Restraints/Challenges

• Complications and Adverse Events

Despite advancements in GI stent technology, complications and adverse events can occur. These can include stent migration, perforation, bleeding, infection, and tissue overgrowth. Such complications can lead to additional treatments, hospitalizations, and increased healthcare costs. Addressing and minimizing these complications is essential for the market's growth.

• Availability of Alternative Treatment Options

In certain cases, alternative treatment options may be available for gastrointestinal conditions, such as surgical interventions or other minimally invasive procedures. The availability of these alternatives can limit the demand for GI stents and pose a challenge for market growth. Manufacturers need to demonstrate the clinical and economic benefits of stent placement compared to alternative treatments.

This global chorea treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chorea treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In December 2020, Boston Scientific announced the launch of its WallFlex Biliary RX Fully Covered Stent with Controlled Release Technology in the United States. The stent is designed to provide controlled release of a drug to help prevent tissue overgrowth
• In November 2020, Cook Medical received FDA clearance for its Evolution Controlled-Release Esophageal Stent. The stent features a dual-layer design that aims to reduce the risk of tissue overgrowth and migration.

Chorea Treatment Market Scope

The global chorea treatment market is segmented on the basis of type, treatment, drugs class, symptoms, end users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Sydenham’s Chorea
• Chorea-Acanthocytosis

Treatment

• Medication
• Surgeries
• Others

Drugs Class

• Antipsychotic Drugs
• Benzodiazepines Drugs

Symptoms

• Involuntary Muscle Movements
• Milkmaid’s Grip
• Speech Problems
• Seizures

End Users

• Clinics
• Hospitals
• Ambulatory Surgical Centres
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Chorea Treatment Market Regional Analysis/Insights

The global chorea treatment market is analysed and market size insights and trends are provided by country, type, treatment, drugs class, symptoms, end users and distribution channel as referenced above.

The countries covered in the global chorea treatment market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

North America dominates the global chorea treatment market because of the strong base of healthcare facilities, presence of high healthcare expenditure and growing research and development activities by major market players for advanced chorea treatment.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, constant rise in geriatric population and growing number of partnership and acquisition agreement by major market players in emerging countries.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global chorea treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global chorea treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global chorea treatment market.

Competitive Landscape and Global Chorea Treatment Market Share Analysis

The global chorea treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global chorea treatment market.

全球舞蹈病治疗市场的一些主要参与者包括：

• 美敦力公司（爱尔兰）
• 波士顿科学公司 (美国)
• ALEVA NEUROTHERAPEUTICS SA（瑞士）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 辉瑞公司（美国）
• 葛兰素史克公司（英国）
• Bausch Health Companies Inc.（加拿大）
• LivaNova, PLC（英国）
• H. Lundbeck A/S（丹麦）
• 益普生（法国）
• Alnylam Pharmaceuticals Inc.（美国）
• Prana Biotechnology Ltd.（澳大利亚）
• RespireRx Pharmaceuticals Inc.（美国）
• Vertex Pharmaceuticals, Inc.（美国）
• SOM Innovation Biotech，SA（西班牙）

SKU-59386